Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

Lisa Sanderson Cox, Christi A. Patten, Raymond Niaura, Paul A. Decker, Nancy Rigotti, David P L Sachs, A. Sonia Buist, Richard D. Hurt

Research output: Contribution to journalArticle

Abstract

BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.

Original languageEnglish (US)
Pages (from-to)828-834
Number of pages7
JournalJournal of General Internal Medicine
Volume19
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Bupropion
Secondary Prevention
Major Depressive Disorder
Depression
Smoking
Placebos
Recurrence
Carbon Monoxide
Air
Outcome Assessment (Health Care)
Interviews
Equipment and Supplies

Keywords

  • Bupropion therapy
  • Major depression
  • Relapse prevention
  • Smoking

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. / Cox, Lisa Sanderson; Patten, Christi A.; Niaura, Raymond; Decker, Paul A.; Rigotti, Nancy; Sachs, David P L; Sonia Buist, A.; Hurt, Richard D.

In: Journal of General Internal Medicine, Vol. 19, No. 8, 08.2004, p. 828-834.

Research output: Contribution to journalArticle

Cox, Lisa Sanderson ; Patten, Christi A. ; Niaura, Raymond ; Decker, Paul A. ; Rigotti, Nancy ; Sachs, David P L ; Sonia Buist, A. ; Hurt, Richard D. / Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. In: Journal of General Internal Medicine. 2004 ; Vol. 19, No. 8. pp. 828-834.
@article{0999dc8dd9a04373b43e3e668b380e33,
title = "Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression",
abstract = "BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54{\%} female, 97{\%} white) were enrolled. Using the Structured Clinical Interview for Depression, 17{\%} of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.",
keywords = "Bupropion therapy, Major depression, Relapse prevention, Smoking",
author = "Cox, {Lisa Sanderson} and Patten, {Christi A.} and Raymond Niaura and Decker, {Paul A.} and Nancy Rigotti and Sachs, {David P L} and {Sonia Buist}, A. and Hurt, {Richard D.}",
year = "2004",
month = "8",
doi = "10.1111/j.1525-1497.2004.30423.x",
language = "English (US)",
volume = "19",
pages = "828--834",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression

AU - Cox, Lisa Sanderson

AU - Patten, Christi A.

AU - Niaura, Raymond

AU - Decker, Paul A.

AU - Rigotti, Nancy

AU - Sachs, David P L

AU - Sonia Buist, A.

AU - Hurt, Richard D.

PY - 2004/8

Y1 - 2004/8

N2 - BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.

AB - BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.

KW - Bupropion therapy

KW - Major depression

KW - Relapse prevention

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=4143147542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143147542&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1497.2004.30423.x

DO - 10.1111/j.1525-1497.2004.30423.x

M3 - Article

VL - 19

SP - 828

EP - 834

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

IS - 8

ER -